The authors examined relations between reproductive factors and 5 estrogen pathway gene polymorphisms (CYP17 rs743572, CYP19A1 rs10046, ERb rs1256049, ERb rs4986938, and COMT rs4680) among 702 Singapore Chinese female lung cancer cases and 1,578 hospital controls, of whom 433 cases (61.7%) and 1,375 controls (87.1%) were never smokers. Parity (per child, odds ratio (OR) ¼ 0.92, 95% confidence interval (CI): 0.87, 0.97) and menstrual cycle length (for 30 days vs. <30 days, OR ¼ 0.50, 95% CI: 0.32, 0.80) were inversely associated with lung cancer in never smokers, while age at first birth (for ages 21-25, 26-30, and 31 years vs. 20 years, ORs were 1.54, 2.17, and 1.30, respectively), age at menopause (for ages 49-51 and 52 years vs. 48 years, ORs were 1.37 and 1.59; P trend ¼ 0.003), and reproductive period (for 31-33, 34-36, 37-39, and 40 years vs. 30 years, ORs were 1.06, 1.25, 1.45, and 1.47; P trend ¼ 0.026) were positively associated. Among smokers, parity was inversely associated with lung cancer, but there was no association with other reproductive factors. The COMT rs4680 A allele was positively associated with lung cancer in never smokers (for G/A or A/A vs. G/G, OR ¼ 1.46, 95% CI: 1.12, 1.90) but not in ever smokers. No associations were seen with other polymorphisms. These results support a risk-enhancing role of estrogens in lung carcinogenesis among never smokers. estrogen; etiology; lung neoplasms; reproductive history Abbreviations: PCR, polymerase chain reaction; SNP, single nucleotide polymorphism.
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Lung cancer is the leading cause of cancer death in the world (1), and smoking is the major risk factor for the disease (2) . However, lung cancer among never smokers is not uncommon, and annual global mortality from lung cancer among never smokers is as high as 15-20 per 100,000 persons (3) . Previous studies suggest that female never smokers may be more likely to develop lung cancer than men (4), although this is disputed (5) . Women appear more likely than men to develop adenocarcinoma, especially among never smokers (6) .
Epidemiologic studies conducted in the 1980s implicated reproductive factors and female hormonal factors in lung carcinogenesis (7) (8) (9) (10) , and this hypothesis gained momentum with evidence of the potential biologic and pathologic roles of estrogen in lung development and carcinogenesis. Estrogen receptors, predominantly the b isoform, are found in both normal lung and carcinomatous tissue (11) , and estrogen receptor signaling pathways are active in lung cancer cells (12) , increasing cell proliferation and promoting angiogenesis. This pathway also interacts with the epidermal growth factor receptor pathway (13) , which is believed to drive carcinogenesis in a subset of lung cancers (lung adenocarcinomas among predominantly female never smokers) (14) . In vitro and mouse model studies suggest that estrogens increase tumor growth, and estrogen receptor antagonists significantly inhibit growth in non-small-cell lung cancer cell lines (15, 16) . These findings have spurred renewed interest in the possible role of female hormonal factors in lung cancer, and, including the earlier studies, at least 28 studies (7) (8) (9) (10) have investigated the association of lung cancer with factors such as parity (8, 9,17-19, 21-29, 31-33, 41) , menstrual history (7-10, 17, 18, 21, 22) , age at menopause (7-10, 18-23, 25, 27, 29, 32, 33, 41) , age at menarche (8-10, 18-23, 26-28, 29, 32, 33, 41) , estrogen replacement therapy (9, 22, 23, 25, 26, 28, 29, (32) (33) (34) (35) (36) (37) (38) (39) , and oral contraceptive use (8, 22, 25, 28-30, 32-34, 4 -41) .
Findings from these studies are inconsistent, suggesting that the effects of female reproductive factors are not strong and therefore difficult to detect, or that reproductive factors interact with other host genetic or environmental factors in complex ways. The existing evidence does not appear to conform to the well-established model for the association of reproductive factors with breast cancer (where early menarche and late menopause, nulliparity, and late age at first birth consistently increase breast cancer risk), but no alternative model has yet emerged.
Understanding the estrogen metabolic pathway in relation to lung cancer may shed light on the role of estrogen in lung carcinogenesis. To date, few studies have examined the association of estrogen-metabolism gene polymorphisms with lung cancer. Two recent studies investigated gene polymorphisms in estrogen-metabolism enzymes (cytochrome P-450 17-a hydroxylase (17,20-lyase) (CYP17), cytochrome P-450 19A1 (aromatase) (CYP19A1), and catechol-O-methyl transferase (COMT)) (42) and in estrogen receptor b (ERb) (43) , although these studies used populations in which nonsmokers were a small minority.
Lung cancer is the leading cause of cancer death in Singapore (44) . Despite low rates of smoking (45) , the incidence of lung cancer among Singaporean Chinese women is unexpectedly high (44) , with a significant proportion of cancers occurring in nonsmokers. This suggests that factors other than smoking may play an unusually important role in lung cancer in this population.
We previously reported that among never smokers, parity and menstrual cycle length were associated with a significantly reduced risk of lung cancer, based on a study of 303 cases and 765 hospital controls (18) . Our aims in the current study were to extend this analysis to a larger group of 702 cases and 1,578 hospital controls so as to better delineate possible differences between smokers and never smokers and to investigate the association of estrogen metabolism gene polymorphisms with lung cancer in Chinese women.
MATERIALS AND METHODS
Data for this study were derived from 2 hospital-based case-control studies conducted in 1996-1998 and 2005-2008 among participants recruited from the 5 major public-sector hospitals in Singapore. Both studies used similar study designs and questionnaires, and methods are reported in detail elsewhere (46, 47) . Eligible cases were Chinese women with incident primary carcinoma of the lung (all histologic types) who were interviewed within 3 months of diagnosis. The average interval between diagnosis and interview was 22 days, and 79% were interviewed within 1 month of diagnosis. A total of 787 eligible lung cancer patients were identified, of whom 702 (89.2%) agreed to participate. Histologic or cytologic reports confirmed the diagnosis of primary lung carcinoma in 673 cases; 29 cases were confirmed on the basis of results from radiologic investigations, where metastatic spread of cancer to the lung was deemed unlikely.
Controls were selected from Chinese female patients admitted to the same hospitals and were frequency-matched for age (within 10 years) and date of admission. Patients admitted for the diagnosis and treatment of cancer or chronic respiratory disease were excluded, and no more than 10% of controls were recruited within a single diagnostic category. Control patients were admitted for a wide range of conditions, with few patients (0.4% of controls) having been admitted for gynecologic or obstetric conditions. The response rate among controls was 91%, with a total of 1,578 controls recruited. Of the 702 cases and 1,578 controls, 433 cases (61.7%) and 1,375 controls (87.1%) were never smokers, defined as never having smoked at least 1 cigarette per day for a year.
Approval for this study was obtained from the institutional review boards of the National University of Singapore and participating health-care institutions. Written consent was obtained from all participants. Trained interviewers administered face-to-face a structured questionnaire which elicited a detailed reproductive history, including parity, age at the birth of the first child, usual menstrual cycle length, age at menarche, and, where relevant, age at menopause. Among postmenopausal women, the reproductive period was measured as the time period between menarche and menopause. Information on exogenous reproductive hormone use (as hormone replacement therapy or oral contraception) was elicited only in the second case-control study. Data on participants' demographic characteristics, occupational history, smoking history, family history of cancer, personal medical history, diet, medication use, and indoor environmental exposures were also obtained.
Blood and/or saliva samples were obtained where consent was given. A total of 559 samples from cases (79.6% of all cases) and 988 samples from controls (62.6% of all controls) were obtained. Genomic DNA was extracted from the buffy coat of 5 mL of whole blood samples using the FlexiGene DNA kit (Qiagen Inc., Hilden, Germany). Saliva DNA was extracted from 2 mL of saliva with the Oragene DNA SelfCollection Kit (DNA Genotek Inc., Kanata, Ontario, Canada), and DNA concentration was measured with the Quantifiler Human DNA Quantification kit (Applied Biosystems (Life Technologies), Foster City, California).
Five polymorphisms in 4 estrogen pathway genes (rs743572 in CYP17, rs10046 in CYP19A1, rs4680 in COMT, and rs1256049 and rs4986938 in ERb) were genotyped. We selected these genes because the proteins they encode are influential in the estrogen pathway. Cytochrome P-450 17-a hydroxylase is an upstream enzyme that produces estrogen precursors, while cytochrome P-450 19A1 converts testosterone to estradiol. Catechol-O-methyl transferase is the rate-limiting enzyme in the detoxification of catechol estrogens (48) . Estrogen receptor b is found in lung tissue. Polymorphisms within these genes were selected for their potential role in affecting the activity of the enzymes, as demonstrated by their location in the gene (promoter regions, the untranslated region, or exons) and by functional and epidemiologic studies. Single nucleotide polymorphisms (SNPs) chosen had to have a minor allele frequency of 5% in Chinese populations.
All SNPs were genotyped on a high-throughput genotyping platform base using a 5#-nuclease allelic discrimination Adjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of cancer in first-degree relatives (no history, history of lung cancer, history of other cancers), smoking status (current, ex-, or never smoker), secondhand smoke exposure at home, and a dummy variable for the study set.
c Adjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of cancer in first-degree relatives (no history, history of lung cancer, history of other cancers), secondhand smoke exposure at home, and a dummy variable for the study set.
d Adjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of cancer in first-degree relatives (no history, history of lung cancer, history of other cancers), duration of smoking (in years), secondhand smoke exposure at home, and a dummy variable for the study set.
e Adjusted for multiple comparisons. f Additionally adjusted for number of children.
assay in a 96-well format, with the ABI StepPlusOne RealTime PCR System (Applied Biosystems). TaqMan universal polymerase chain reaction (PCR) master mix and predesigned SNP genotyping assay mix containing PCR primers and probes were purchased from Applied Biosystems. Among 131 subjects who had both blood and saliva samples, saliva DNA was successfully genotyped from 89%, while all blood DNA samples were successfully genotyped. The genotypes from saliva DNA samples matched completely (100%) those of the corresponding blood DNA samples. Three positive controls and 2 negative controls were included in each 96-well plate, and 10% of DNA samples were genotyped in duplicate for each polymorphism. The concordance rate for the duplicate analyses was 100%. Call rates for the 5 SNPs studied ranged from 96.6% to 97.5%. A set of 10 adjustment variables, chosen on the basis of biologic considerations and reverse stepwise analyses of the data set, were used: age at diagnosis, country of birth, housing type, number of years of education, smoking status, secondhand smoke exposure, history of cancer in a first-degree relative, mean intake of fruits and vegetables (servings/week), and a variable to indicate which case-control study the participant belonged to. Among current and former smokers, duration of smoking (in years), the logarithm of the average number of cigarettes smoked per day, and time (in years) since quitting smoking prior to diagnosis (set at 0 for current smokers) were independent risk factors (not shown). Logistic regression models using combinations of these 3 variables showed that smoking duration alone adequately explained the variation in risk attributable to smoking, and this was added as an adjustment variable for smokers.
Unconditional logistic regression was used, and odds ratios and 95% confidence intervals were calculated. Tests for linear trend were performed by entering the factor of interest into the logistic regression model as an ordinal variable, where each successively higher category in that factor was assigned a higher numeric value in the variable. The likelihood ratio test was used to test for interaction between factors. Adjustment for multiple comparisons was made for all tests of statistical interaction using the method of Benjamini and Hochberg (49) . All P values calculated were 2-tailed, and significance was set at P < 0.05. We used Stata statistical software, version SE 10.1 (StataCorp LP, College Station, Texas), for data analyses. All SNPs studied were in Hardy-Weinberg equilibrium in the control population.
RESULTS
Cases were significantly younger than controls and consumed less fruit and vegetables. They were more likely to have been born in China, to live in private housing, to smoke, to report daily secondhand smoke exposure, and to have a positive family history of lung cancer in a first-degree relative. Among smokers, cases reported a longer duration of smoking (Table 1) . Half of the cases (51.7%) had lung adenocarcinoma, and the proportion of adenocarcinomas was higher among never smokers (62.6%) than among smokers (34.2%).
High parity was associated with a lower risk of lung cancer in never smokers (for every additional child, odds ratio (OR) ¼ 0.92, 95% confidence interval (CI): 0.87, 0.97).
Similar odds ratios, but with nonsignificant P values, were obtained in the smaller number of ever smokers (Table 2) . Higher age at first birth was associated with an increased risk of lung cancer in never smokers (among those whose first child had been born when they were aged 21-25, 26-30, and 31 years, odds ratios were 1.54, 2.17, and 1.30, respectively, compared with those aged 20 years at the first birth). The effect was less clear among ever smokers (adjusted P interaction ¼ 0.14) ( Table 2 ).
Age at menopause was associated with lung cancer among postmenopausal women who had never smoked (for ages at menopause of 49-51 years and 52 years compared with 48 years, odds ratios were 1.37 and 1.59, respectively; P trend ¼ 0.003) but not among those who had ever smoked (odds ratios were 0.95 were 0.94, respectively; P trend ¼ 0.81); the adjusted P value for interaction was 0.22) ( Table 2) . Similarly, a longer reproductive period was associated with lung cancer risk among never smokers (for reproductive periods of 31-33, 34-36, 37-39, and 40 years compared with 30 years, odds ratios were 1.06, 1.25, 1.45, and 1.47, respectively; P trend ¼ 0.026) but not among ever smokers (adjusted P interaction ¼ 0.34) ( Table 2) .
Long menstrual cycle lengths were protective in never smokers (for reported cycle lengths of >30 days vs. 30 days, OR ¼ 0.50, 95% CI: 0.32, 0.80) but not in ever smokers (adjusted P interaction ¼ 0.33). There were relatively few women who reported cycle lengths longer than 30 days. There was no association between hormone use and lung cancer, although the prevalence of hormone use was low. There was also no association between age at menarche and lung cancer ( Table 2) .
Of the 5 SNPs studied, only the SNP in the COMT gene was associated with lung cancer (Table 3 ). The A allele at rs4680 was associated with lung cancer in never smokers (for the G/A or A/A genotype compared with the G/G genotype, OR ¼ 1.46, 95% CI: 1.12, 1.90) but not in ever smokers (OR ¼ 0.77, 95% CI: 0.47, 1.28; adjusted P interaction ¼ 0.14).
In analyses stratified by age, the risk-conferring effect of longer reproductive periods in never smokers was seen only among women older than 65 years, not in the younger age group (adjusted P interaction ¼ 0.22). The protective effect of increasing parity also appeared to be stronger in the older age group than in the younger age group, although this interaction was not statistically significant (adjusted P interaction ¼ 0.95) ( Table 4 ). The effects of age at menopause, age at first birth, menstrual cycle length, and the COMT rs4680 polymorphism were not modified by age (data not shown). Odds ratio estimates for never-smoker cases restricted to persons with a confirmed histology of adenocarcinoma were similar to those obtained for all never smokers (data not shown). Further adjustment for self-reported exposure to cooking fumes shifted odds ratio estimates for all reproductive factors and SNPs by less than 5% in either direction.
DISCUSSION
In this ethnically homogenous population with a high prevalence of never smoking, later age at menopause, longer reproductive period, later age at first birth, short menstrual cycle length, and low parity were associated with lung cancer, particularly among never smokers. Low parity is associated with higher blood estrogen levels (50). Shorter menstrual cycles suggest an overall increase in the period of unopposed estrogen exposure, and late menopause and long reproductive periods imply more reproductive cycles over the lifetime and hence longer periods of estrogen exposure in total. Our results are therefore consistent with an association between higher levels of endogenous estrogen exposure over the lifetime and risk of lung cancer.
An association with reproductive history was previously observed in our first study involving a smaller group of participants (18) , where high parity and long menstrual cycles were protective. In the current analysis, we additionally found an increased risk associated with later age at first birth, later age at menopause, and longer reproductive period. In a recently published Singapore cohort study, Seow et al. (32) reported similar protective effects for parity among female Chinese never smokers, although they did not find a significant association with age at menopause. While we are not able to fully explain this particular difference, we feel that, taken as a whole, data from this population suggest a role for estrogens in lung carcinogenesis among never-smoking women.
In other published studies, investigators have reported results similar to ours-namely, a protective effect of higher parity (18, 29, (31) (32) (33) and increased risk with higher age at menopause (7) (8) (9) . In a cohort study, Liu et al. (23) did not find a main effect with menarche or menopause, but they reported that, compared with women with a late age at menarche (>15 years) and an early age at menopause (<51 years), women with either early menarche or late menopause had a higher risk of lung cancer. They proposed that the length of (8, 9, 19, 21-23, 25-27, 41) or increased risk (24, 28) with regard to parity, reduced risk with later age at menopause (19, 20, 29, 41) , and reduced risk with a longer reproductive period (29) . The inconsistency in findings across the various studies may be due to differences in the study populations. Studies conducted in smokers or in populations containing a high proportion of smokers might not have been able to detect a weaker effect of estrogens. There is growing evidence that smoking-related lung cancer and never-smoker lung cancer are etiologically distinct. It is plausible that the effect of estrogens may apply specifically to lung cancer among never smokers, given that mutations in the epidermal growth factor receptor gene (EGFR) appear to be key drivers of this disease (14) and the estrogen pathway interacts at the cellular level with the epidermal growth factor receptor signaling pathway (13) . In a recent Japanese case-control study, Matsuo et al. (27) noted that the increased risk associated with longer reproductive periods was seen only in EGFR mutation-positive cancers.
The effect of estrogen may be modified by other biologic factors. For example, Paulus et al. (31) proposed that the different age distributions of women in the studies may explain the inconsistency of results with regard to parity, and their own data suggested that the effect of parity was seen only in late-onset lung cancer (using a cutoff of 50 years), thus suggesting that high parity may protect against postmenopausal lung cancer but not premenopausal lung cancer. We also found that both longer reproductive periods and parity had more convincing effects in older women, although the possible reasons for this are yet to be elucidated.
We did not find an association with key polymorphisms in the estrogen metabolism pathway, other than the rs4680 polymorphism in the COMT gene, where the A allele was associated with lung cancer in never smokers. The oxidative metabolism of 17b estradiol and estrone to catechol estrogens is postulated to be a risk factor in carcinogenesis: Catechol estrogens are oxidized to quinines that can form DNA adducts and produce DNA-and lipid-damaging reactive oxygen species (48) . Catechol-O-methyl transferase methylates (thus eliminating) catechol estrogens and is the key rate-limiting enzyme in that pathway (48) . The A allele at rs4680 (codon 158) results in a point mutation, substituting the amino acid methionine for valine (51) . Val/Met and Met/Met genotypes appear to have lowered enzymatic activity, with consequently increased cellular levels of catechol estrogens. Two other case-control studies have investigated the effect of polymorphisms at this site on lung cancer risk, with similar results. The Met/Met and Val/Met genotypes were also associated with an increased risk of lung cancer in a population of smokers (52). Cote et al. (42) found that the A allele had no independent effect in a group of subjects who were predominantly smokers, but lung cancer risk was increased among those with the A allele and a glutathione S-transferase M1 (GSTM1) null genotype in comparison with those with the G/G genotype and a GSTM1 nonnull genotype. In that same study, an independent effect of rs743572 (in CYP17) on lung cancer risk was not seen, although the C allele in combination with risk alleles in GSTM1 and GSTT1 increased risk (42) . The authors did not find a relation between CYP19A1 and lung cancer, although the polymorphism they studied (the tetranucleotide tandem repeat in intron 4) was different from the one studied here. Paulus et al. (43) , examining 4 ERb SNPs (the same 2 as in our study, and 2 others), did not find an association of individual SNPs or haplotypes with lung cancer risk, which is consistent with our results.
We had anticipated that polymorphisms in CYP19A1 and CYP17 would be important if the effect of reproductive factors is mediated through estrogen levels in target tissue (such as the lungs). However, current evidence, including ours, is more consistent with a risk-conferring effect of catechol estrogens on lung carcinogenesis. Few studies have examined estrogen pathway polymorphisms in lung carcinogenesis, and further work is necessary to determine whether this hypothesis is true. Inclusion of more SNPs for which functional studies indicate an effect on enzyme activity or estrogen levels, or a systematic interrogation of polymorphisms in the CYP19A1, CYP17, and COMT genes for associations with lung cancer, may be useful in this regard.
We noticed suggestive interactions between smoking status and the COMT SNP and age at first birth, and between age and reproductive period among never smokers. However, our study did not have adequate statistical power to detect interactions, and the interactions were no longer significant after adjustment for multiple testing. Further research using larger study populations is needed to confirm these observations.
The strengths of our study include homogeneity with regard to gender and ethnicity and the large number of never smokers, which allowed detailed investigation of risk factors pertinent to this group. This is particularly important in the light of recent understanding that smoking lung cancer and nonsmoking lung cancer may be different diseases. Methodological limitations associated with the case-control study design are well-known, and we attempted to address these limitations in a variety of ways. Reporting bias is unlikely to have been a major problem, as the relation between reproductive factors and lung cancer has rarely been reported in popular media, and participants were asked about reproductive factors in the context of a long questionnaire investigating a variety of factors. We assessed interviewer bias by recording and reviewing a random subset of interviews. To reduce bias introduced by the use of hospital controls, we chose controls from a wide variety of admitting diagnoses, and gynecologic diseases as the admitting diagnoses were very rare among our controls (about 0.4% of controls).
Our study suggests that reproductive factors are involved in lung carcinogenesis, particularly among never smokers. However, the specific functional role of estrogens in lung cancer is still not known, and while our data suggest a role for catechol estrogens, the mechanisms involved are likely to be complex. Given the relation between the estrogen and epidermal growth factor receptor pathways and the significance of the latter in lung cancer among never smokers, it is clear that further studies, both mechanistic and epidemiologic, are needed in this area.
